Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC-Reference-Cited by-同舟云学术

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Published:2018-10 Issue:10 Volume:13 Page:1560-1568
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Riess Jonathan W.,Gandara David R.,Frampton Garrett M.,Madison Russell,Peled Nir,Bufill Jose A.,Dy Grace K.,Ou Sai-Hong Ignatius,Stephens Philip J.,McPherson John D.,Lara Primo N.,Burich Rebekah A.,Ross Jeffrey S.,Miller Vincent A.,Ali Siraj M.,Mack Philip C.,Schrock Alexa B.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Phase III Study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

4. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6;Yang;Lancet Oncol,2015

5. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor;Jia;Cancer Res,2016

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of flavonoid-containing compound Lupalbigenin as anti-NSCLC cancer agents via suppression of EGFR and ERK1/2 pathway;Bioorganic Chemistry;2024-09

2. Current clinical practice and physicians’ insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation;BMC Cancer;2024-08-23

3. Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study;BMC Cancer;2024-08-14

4. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

5. Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta;Current Oncology;2024-07-31